about
Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer TherapyIntrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and FunctionHypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance.Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.New insights into the role of EMT in tumor immune escape.Aptamer-PEG-modified Fe3O4@Mn as a novel T1- and T2- dual-model MRI contrast agent targeting hypoxia-induced cancer stem cells.Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production.Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer.Modulating tumor hypoxia by nanomedicine for effective cancer therapy.Integrating the UPRmt into the mitochondrial maintenance network.Malignant Mesothelioma: Time to Translate?Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo.Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling.Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells.Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.Pentose Shunt, Glucose-6-Phosphate Dehydrogenase, NADPH Redox, and Stem Cells in Pulmonary Hypertension.Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity.Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.Application of Sodium Selenite in the Prevention and Treatment of Cancers.Stromal-epithelial lactate shuttle induced by tumor‑derived interleukin‑1β promotes cell proliferation in oral squamous cell carcinoma.Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT
P2860
Q26740207-B91A6523-EF9B-4ED2-B831-0E2871BBFBBEQ26749556-0002A2A7-941B-419B-9DD7-3699764C9DBAQ33827896-26CE3979-7DA7-4461-9E5D-53736F439967Q33834080-D3E89019-BD06-406F-822A-1A2938F5A5F4Q33869781-C9A848D8-E3A3-46CB-AB8A-6D489077965AQ37504779-9699DAB3-A8DA-4C49-B58F-50E43498E55FQ37662257-64262B03-0ABC-423F-A855-0960CAE6CC8FQ37688288-3A73F1EC-DEC7-42C6-8802-737939EE6730Q38961080-A3DD1BB9-607C-41F2-855C-38A1F0BF9AC8Q39170182-6785A6A0-0CDA-4F6F-8CD0-36A25A7EFF82Q39366003-C2219C28-C1E8-4989-A3B9-33215D1542CEQ40980867-41362D39-4FC7-4FFC-973A-2B1B4BF47DEAQ41003127-DE68A83E-0995-4ECD-8249-CDB0C5424326Q41701341-780A29EF-6CA1-4644-B639-2C471B1FA57BQ42317488-EC203821-98ED-4EB3-A701-0EDAE79511EBQ42511795-208F8540-DD68-4236-A608-6DAF3BFF187FQ46280894-E376D041-B9E8-4962-B855-20D1015021E6Q47120916-0BA7DCFC-F32F-447B-AF75-C1DE7A919DC3Q47121012-2C6D3830-EB6B-4647-908C-9654289871B8Q47422547-32D33CF4-1ABA-4046-AE03-76B0B31DF4F3Q50066233-E6BFB14B-0E07-43C0-8216-EC15A818093DQ52726721-8EF5E48B-D703-4FD0-8257-1769B3706C20Q57109688-DF635CFC-80B9-4970-821B-EF9FAF044D5B
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Targeting hypoxic response for cancer therapy
@ast
Targeting hypoxic response for cancer therapy
@en
Targeting hypoxic response for cancer therapy
@nl
type
label
Targeting hypoxic response for cancer therapy
@ast
Targeting hypoxic response for cancer therapy
@en
Targeting hypoxic response for cancer therapy
@nl
prefLabel
Targeting hypoxic response for cancer therapy
@ast
Targeting hypoxic response for cancer therapy
@en
Targeting hypoxic response for cancer therapy
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Targeting hypoxic response for cancer therapy
@en
P2093
Federica Gemignani
Marija Krstic-Demonacos
Stefano Landi
P2860
P304
13464-13478
P3181
P356
10.18632/ONCOTARGET.7229
P407
P5008
P577
2016-03-22T00:00:00Z